Differential transcriptional expresi??n of the polymorphic myxovirus resistance protein A in response to interferon-alpha treatment
- 1 March 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Pharmacogenetics
- Vol. 14 (3), 189-193
- https://doi.org/10.1097/00008571-200403000-00007
Abstract
Levels of myxovirus resistance protein A (MxA) mRNA were studied for a single nucleotide polymorphism in the promoter region at nucleotide position -88 of the gene to identify individual-specific responses to interferon (IFN)-alpha2 that might predict responsiveness to IFN-alpha therapy. We quantified MxA expression by reverse transcription and real-time polymerase chain reaction in peripheral blood mononuclear cells (PBMC) in vitro, induced by IFN-alpha2, from 22 healthy donors, in relation with G/T polymorphism located in the promoter of the MxA. MxA mRNA was significantly upregulated in all subjects (mean of 53-fold) in response to IFN-alpha2 in vitro (P < 0.01). Comparison of the inducibility of MxA mRNA expression in relation with G/T polymorphism showed a 4.26-fold higher induction of MxA mRNA levels in PBMC from carriers of the mutant allele (GT or TT) than homozygotes with the wild-type allele (GG) (P < 0.001). We propose that expression of the IFN-inducible MxA is affected by a single nucleotide polymorphism in the MxA promoter which can identify an individual response to IFN-alpha2.Keywords
This publication has 24 references indexed in Scilit:
- Cancer immunotherapy: The interferon-α experienceSeminars in Oncology, 2002
- Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled TrialsJournal of Clinical Oncology, 2002
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001
- Evaluation of bioavailability of three types of IFNβ in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantificationJournal of Immunological Methods, 2001
- Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MSNeurology, 2000
- Correlation of Interferon-Induced Expression of MxA mRNA in Peripheral Blood Mononuclear Cells with the Response of Patients with Chronic Active Hepatitis C to IFN-alpha TherapyJournal of Interferon & Cytokine Research, 1999
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 1998
- HOW CELLS RESPOND TO INTERFERONSAnnual Review of Biochemistry, 1998
- The Treatment of Chronic Viral HepatitisNew England Journal of Medicine, 1997
- Virus interference. I. The interferonProceedings of the Royal Society of London. Series B - Biological Sciences, 1957